Ai2 Raises £1.75M
Summary
Ai2 Limited, a Manchester, UK-based company that has developed proprietary human protein-like substances which inhibit bacteria, fungi and viruses, has raised £1.75m in funding.Backers include managers of The North West Fund for Biomedical, SPARK Impact, which injected £800k, and MTI Firms, managers of UMIP Premier Fund, which committed £950k.The Manchester University spin-out will use the funds to continue to develop its technology.Led by CEO Dr Jim McNairney, Ai2’s products, proprietary human protein-like substances, can be used to prevent infection on a wide range of commonly used medical devices like urinary catheters and stents as well being utilised in wound dressings and consumer products.FinSMEs 06/01/2012
Funding
Amount
$2.7M
Total raised
Date
January 6, 2012
Announcement date
Investors
MTI Partners, The North West Fund
Lead investors
Company
ai2.com
Funded company
Classifications
industries
No industries detected
applications
Web and Content Management
AskAI Classifications
Labels
Software
SaaS
Mobile Applications
Linked Companies
Ai2
$1M to $5M